Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project.

Marina Cazzaniga,Eva Ciruelos,Alessandra Fabi,José Ángel García-Sáenz,Henrik Lindman,D. Mavroudis,C. Schem,G. Steger,E. Timotheadou,K. Zaman,Valter Torri

Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project.

2019

Marina Cazzaniga
Eva Ciruelos
Alessandra Fabi
José Ángel García-Sáenz
Henrik Lindman
D. Mavroudis
C. Schem
G. Steger
E. Timotheadou
K. Zaman
Valter Torri

Introduction Despite the large use of nab-paclitaxel as a treatment option in metastatic breast cancer (MBC) across different countries, no definitive data are available in particular clinical situations.

Keywords:

Nab-paclitaxel
Breast cancer
Pharmacology
HER2 negative
Oncology
Internal medicine
Metastatic breast cancer
Medicine
expert consensus
locally advanced
Paclitaxel
Survival rate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations